Nutrients in the Prevention of Alzheimer’s Disease

Anna Laura Cremonini, Irene Caffa, Michele Cea, Alessio Nencioni, Patrizio Odetti, and Fiammetta Monacelli

Department of Internal Medicine and Medical Specialties, Section of Geriatrics, IRCCS Ospedale Policlinico San Martino, Genova, Italy

Correspondence should be addressed to Fiammetta Monacelli; fiammetta.monacelli@unige.it

Received 15 May 2019; Accepted 2 August 2019; Published 4 September 2019

Copyright © 2019 Anna Laura Cremonini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alzheimer’s disease (AD) is a disease caused by the complex interaction of multiple mechanisms, some of which are still not fully understood. To date, pharmacological treatments and supplementation of individual nutrients have been poorly effective in terms of the prevention and treatment of AD, while alternative strategies based on multimodal approaches (diet, exercise, and cognitive training) seem to be more promising. In this context, the focus on dietary patterns rather than on single food components could be more useful in preventing or counteracting the pathological processes typical of AD, thanks to the potential synergistic effects of various nutrients (neuronutrients). The aim of this narrative review is to summarize the currently existing preclinical and clinical evidence regarding the Mediterranean diet (MeDi), the Dietary Approaches to Stop Hypertension (DASH) diet, and the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet, which are three dietary patterns with well-known anti-inflammatory and antioxidant properties. Recently, they have been related to brain protection and AD prevention, perhaps thanks to their high content of neuroprotective bioactive compounds. Similarly, intermittent fasting (IF) or calorie restriction (CR) is emerging as interesting approaches that seem to promote hippocampal neurogenesis, activate adaptive stress response systems, and enhance neuronal plasticity, thus leading to motor and cognitive improvements in animal models of AD and hopefully also in human beings.

1. Introduction

Alzheimer’s disease (AD) is a disease of later life, affecting one in four people 85 years of age or over, and the incidence is expected to rise in the coming years, with 131.5 million estimated cases by 2050 [1]. To date, approved drugs have shown modest clinical benefits in delaying the neurodegenerative process, and currently, the AD epidemic is facing two major challenges. Both the lack of disease modifying drugs and the need to delay cognitive-related disability and frailty trajectories highlight the necessity to develop nonpharmacological strategies to stop this ever-increasing global burden. In line with this, previous studies, including the milestone Rotterdam study, have pointed out the relevance of nutrition in counteracting brain neurodegeneration [2].

Although several nutritional approaches have been considered as possible alternatives to the currently existing drugs for AD, this line of research has only been partially explored and has not resulted in any solid evidence [3, 4].

The neuropathology and etiology of AD indicate a complex series of molecular mechanisms is involved, including the amyloid hypothesis, mitochondrial dysfunction, oxidative stress, and brain neuroinflammation as the mainstream molecular pathways [5]. In turn, the neuroinflammatory cascade may be synergistically associated with immunosenescence and gut dysbiosis, intercepting the trajectories of the aging brain and the progression to dementia [6].

Recent evidence has indicated that epigenetics could help shed light on such a complex neurodegenerative pattern. DNA methylation, histone modifications, and microRNAs...
are the principal epigenetic mechanisms involved in AD pathophysiology. In line with this, nutrition is believed to be a modifiable environmental factor that seems to strongly impact on AD pathology by modulating its phenotypic expression [7, 8].

Therefore, recent literature reports have underlined the protective role of a number of individual food components, including micro- and macronutrients in the prevention and management of AD [9, 10]. Several researchers have explored the role of single food components, as well as lifestyle habits and inappropriate diets in facilitating the development of AD and its clinical progression. By virtue of the role of cardiovascular risk factors in the onset of AD [11], nutritional approaches targeting insulin resistance, dyslipidemia, and oxidative stress have been found to ameliorate the related clinical conditions, such as diabetes, metabolic syndrome, and dyslipidemia [12–14].

In keeping with the understanding of the complex interplay between nutrition and AD, a multinutrient approach has also been developed which is based on the rationale that multiple dietary molecules can interact in a synergistic manner to modulate several AD molecular hallmarks.

Namely, omega-3 fatty acids, vitamin B and E, choline, and uridine have provided the rationale for improving effectiveness in AD prevention and clinical management. However, to date, no clinical evidence that this putative nutritional supplementation prevents AD onset or progression has been reported [15]. Based on the current findings, it is unlikely that a single food component or a multinutrient supplementation actually represents the right way to prevent the development of AD or slow down its progression.

However, the interactions among several individual nutrients seem to provide the ground for effectiveness with respect to dementia prevention in older adults.

Another important aspect is that all the theoretical evidence that has been collected so far shows a series of pitfalls that hamper practical concepts and the clinical transferability of results.

The main limitations that prevent bench to bedside translation may be related to the experimental conditions and the pharmacological concentrations of the specific food components that hardly mimic human dietary intake and daily recommended doses. Although animal studies seem to be promising, few and contradictory results have been observed in human trials [16]. Moreover, the heterogeneity of the study designs and the paucity of large scale clinical epidemiological and observational studies on the causal link between nutrition and AD make the results even more difficult to understand.

Besides these issues, strategies that focus on dietary patterns rather than on an approach based on individual foods or nutrients seem to provide a unifying conceptual framework between nutrition and AD; the various components or “neuronutrients” included in a good dietary pattern can offer potential synergistic and neuroprotective effects [16–18].

Adopting this as our starting point, our review will summarize the latest developments regarding the use of dietary patterns in older adults as a way to prevent AD.

Thus, studies whose outcomes include “cognitive functions” or “global cognitive performance” or the incidence of a generic “cognitive decline” or “cognitive impairment” will not be taken into consideration.

2. Mediterranean Diet (MeDi) and AD Prevention

The Mediterranean diet (MeDi) would appear to be promising for AD prevention, including the earlier predementia stages. Indeed, the MeDi diet, based on traditional eating habits in Greece, Southern Italy, and other Mediterranean regions, albeit with regional differences, is characterized by high consumption of fruits and vegetables, cereals, legumes, olive oil, nuts, and seeds as the major source of fats, moderate consumption of fish, low to moderate consumption of dairy products and alcohol (wine), and low intake of red and processed meats (see Table 1). It can be considered a nutritional model for healthy dietary habits since it contains all the essential nutrients including monounsaturated fatty acids (mainly in olive oil), polyunsaturated fatty acids (in fatty fish), antioxidants (e.g., allium sulphur compounds, anthocyanins, beta-carotene–flavonoids, catechins, carotenoids, indoles, or lutein), vitamins (A, B1, 6, 9, 12, D, and E), and minerals (magnesium, potassium, calcium, iodine, zinc, and selenium) [19]. Growing evidence indicates the neuroprotective potential of the MeDi, thus supporting the rationale that adherence to this dietary pattern can be a preventative approach towards reducing the risk of cognitive decline, mild cognitive impairment (MCI), and AD [20, 21].

2.1. Epidemiological Evidence (See Table 2). Two cross-sectional studies [22, 23] showed an inverse correlation between the Mediterranean diet and AD in older American and Australian adults. In the first study [22], which was performed on a cohort of elderly American subjects living in New York, the MeDi score (which is a 9-point scale developed on the basis of the eating habits of a Greek population, with higher scores indicating greater adherence) was the main predictor of AD status in logistic regression models adjusted for potential confounders for both AD (age, sex, ethnicity, education, apolipoprotein E genotype, caloric intake, smoking, medical comorbidity index, and body mass index) and for vascular risk factors (dyslipidemia, hypertension, and coronary heart disease) that should be considered possible mediators in the pathogenesis of AD. Higher adherence to the MeDi was associated with a significantly lower risk of AD, considering MeDi adherence both as a continuous and a categorical variable [24]. In the second cross-sectional study, Gardener et al. [23] replicated these results in an Australian population of older adults participating in the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) study. As compared to healthy controls, subjects with a diagnosis of MCI or AD had a lower mean MeDi score, and every 1-unit increase in the MeDi score was associated with a 19–26% decrease in the odds of being in the AD category.

Several prospective studies have been published in the last 15 years examining the role of the MeDi diet in reducing the risk of dementia and AD. Numerous US population-
based studies having a median follow-up of 3–5.4 years revealed that greater adherence to the MeDi was associated with a reduced risk of AD [25–28], a lower risk of developing AD in patients with MCI [29], and lower mortality in AD patients, suggesting a possible role of MeDi in modulating not only the pathogenetic pathways but also the subsequent course of AD [30]. A more recent longitudinal study conducted in a Greek population as part of the Hellenic Longitudinal Investigation of Ageing and Diet (HELIAD) [31] evaluated adherence to the MeDi pattern using a more complicated score, i.e., the Mediterranean Dietary Score (MedDietScore) [32]. The authors of the HELIAD study found that each unit increase in the MedDietScore was associated with a 10% decrease in the odds of dementia.

Unlike the previously mentioned studies, three other prospective studies found no association. In a French study, MeDi adherence was not associated with a risk of incident dementia or AD as a continuous or as a categorical variable [33]. In another study, Roberts et al. reported a 25% reduced risk of MCI or dementia in subjects in the upper tertile of the MeDi score at baseline, but this association did not reach statistical significance, possibly due to the relatively short follow-up (median follow – up = 2.2 years) [34]. In the third one, Olsson et al. found no correlation between MeDi adherence and the risk of AD or all-type dementia in a cohort of 1,138 elderly Swedish men followed-up for 12 years [35].

Several systematic reviews and meta-analyses of both case-control and longitudinal studies confirmed the association between higher adherence to MeDi and a reduced risk of stroke, depression, and neurodegenerative diseases (cognitive decline, dementia, MCI, AD, and Parkinson’s disease), albeit with some contradictory results [36–41]. Several factors can at least partly explain these differences in results. The first one is the use of different methods for evaluating eating habits (0 to 9 score, 0 to 55 score, and others): these scores are usually validated in a specific population having specific characteristics, eating habits, and culture. Therefore, they cannot easily be applied to other populations, especially non-Mediterranean ones, such as the Americans or Australians. As already discussed with regard to the assessment of MeDi adherence, the two most commonly used scores are the Trichopoulou’s 0 to 9 score [24] and the Panagiotakos’s 0 to 55 score [32]. The use of these two scoring systems has been extensively reported in the literature and both have proven to be reliable and valid tools for assessing adherence to the Mediterranean diet, but they are both based on the typical eating habits of the Greek population, so it is difficult to apply these scores to non-Mediterranean populations. Moreover, there is broad heterogeneity in the study characteristics,

| Dietary pattern | Characteristics | Low consumption |
|----------------|----------------|-----------------|
| Mediterranean diet (MeDi) | Whole-grain cereals (1-2 s every main meal) Vegetables (≥2 s/every main meal) Fruits (1-2 s/every main meal) Olive oil (every main meal) Olives/nuts/seeds (1-2 s/every day) Low-fat diaries (2 s/every day) Herbs/spices/garlic/onions (every day) Eggs (2-4 s/week) White meat (2 s/week) Fish/seafod (≥2 s/week) Potatoes (≤3 s/week) Legumes (≥2 s/week) (Red) wine | Added salt Red meat (<2 s/week) Processed meat (<1 s/week) Sweets (≤2 s/week) |
| Dietary Approaches to Stop Hypertension (DASH) | Whole-grain products (every day) Vegetables (every day) Fruits (every day) Dairy (moderate-to-high consumption) Poultry (2 s/week) Fish/seafod (1-2 s/week) Legumes (2 s/week) | Saturated fats Total fats Salt (sodium) Sweetened beverages Red and processed meats |
| Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) | Green leafy vegetables (≥6 s/week) Other vegetables (≥1 s/day) Nuts (≥5 s/week) Berries (≥2 s/week) Beans (≥3 s/week) Whole grains (≥3 s/day) Fish (≥1 s/week) Poultry (≥2 s/week) Olive oil (primary oil used) (Red) wine (1 glass/day) | Red meats (<4 s/week) Butter and stick margarines Cheese (<1 s/week) Pastries and sweets (<5 s/week) Fried or fast food (<1 s/week) |
| Authors (year)                  | Type of diet | Study design      | Study population | Results                                                                                                                                                                                                 | Follow-up/length of intervention | Reference |
|-------------------------------|--------------|-------------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-----------|
| Scarmeas et al. (2006)        | MeDi         | Cross-sectional   | Elderly Americans (NY) | Higher adherence to the MeDi was associated with lower risk for AD (odds ratio, 0.76; 95% confidence interval, 0.67-0.87; P<0.001) Compared with healthy controls, subjects with AD and MCI had a lower mean MeDi score (P<0.001 and <0.05, respectively); each additional unit in the MeDi score was associated with 13–19% lower odds of being in the MCI category, and 19–26% lower odds of being in the AD category | NA                              | [22]      |
| Gardener et al. (2012)        | MeDi         | Cross-sectional   | Elderly Australians | Higher adherence to the MeDi was associated with significantly lower risk for development of AD. Each additional unit of the MeDi score was associated with 9 to 10% less risk for development of AD                                                                 | NA                              | [23]      |
| Scarmeas et al. (2006b)       | MeDi         | Cohort            | Elderly Americans (NY) | Both higher Mediterranean-type diet adherence and higher physical activity were independently associated with reduced risk for AD                                                                                                                                  | 4 years                         | [25]      |
| Scarmeas et al. (2009)        | MeDi         | Cohort            | Elderly Americans (NY) | Significant association between MeDi score and reduction in risk of AD: compared to those in the lowest tertile of MeDi, subjects in the highest tertile had a 34% less risk of developing AD (p-for-trend = 0.04)                                                                 | 5.4 years                       | [26]      |
| Gu et al. (2010)              | MeDi         | Cohort            | Elderly Americans (NY) | Participants in both the middle and the highest tertiles of MIND scores had a statistically significant reduction in AD rate compared to those in the lowest tertile (53% and 35% reduction, respectively). Subjects with the highest adherence to the MeDi and DASH had a 54% and 39% lower risk of developing AD, respectively, compared to those in the lowest tertile (HR = 0.46, 95% CI 0.26, 0.79) | 3.8 years                       | [27]      |
| Morris et al. (2015)          | MeDi DASH    | Cohort            | Elderly Americans (Chicago) | Significant association between MeDi adherence and MCI conversion to AD, with a 48% less risk of developing AD (HR: 0.52; 95% CI: 0.30, 0.91; P = 0.02) for highest vs. lowest tertile on MeDi score                                                                 | 4.5 years                       | [28]      |
| Scarmeas et al. (2009b)       | MeDi         | Cohort            | Elderly Americans (NY) | Higher adherence to the MeDi is associated with lower mortality in AD patients                                                                                                                                   | 4.3 years                       | [29]      |
| Scarmeas et al. (2007)        | MeDi         | Cohort            | Elderly Americans (NY) | Adherence to MeDi is positively associated with a decreased likelihood of dementia and better                                                                                                               | 4.4 years                       | [30]      |
| Anastasiou et al. (2017)      | MeDi         | Cross-sectional   | Elderly Greeks     |                                                                                                                                                                                                        | NA                              | [31]      |
| Authors (year)                  | Type of diet | Study design | Study population                   | Results                                                                 | Follow-up/length of intervention | Reference                        |
|--------------------------------|--------------|--------------|-------------------------------------|------------------------------------------------------------------------|-----------------------------------|-----------------------------------|
| Martinez-Lapiscina et al. (2013)| MeDi         | RCT (PREDIMED) | Individuals at high CV risk (from Spain) | A dietary intervention with MeDi enriched with either EVOO or nuts appears to improve cognition compared with a low-fat diet | 6.5 years                        | [43]                              |
| Valls-Pedret et al. (2015)     | MeDi         | RCT (PREDIMED) | Individuals at a high CV risk (from Spain) | A MeDi supplemented with EVOO or nuts is associated with improved composite measures of cognitive function | 4.1 years                        | [44]                              |
| Knight et al. (2016)           | MeDi         | RCT (MedLey)  | Elderly Australians                 | No evidence of a beneficial effect of a MeDi intervention on cognitive function among healthy older adults | 6 months                         | [45]                              |
| Marseglia et al. (2018)        | MeDi         | RCT (NU-AGE)  | Five European populations           | Improved cognitive performance in both the active and the control groups, with no additional diet-related cognitive improvements | 1 year                           | [46]                              |
| Tangney et al. (2014)          | MeDi         | Cohort       | Older Americans (Chicago)           | A 1-unit difference in DASH score and in MedDietScore are associated with a slower rate of global cognitive decline by 0.007 standardized units (standard error of estimate = 0.003, \( P = 0.03 \)) and by 0.002 standardized units (standard error of estimate = 0.001, \( P = 0.01 \)), respectively | 4.1 years                        | [67]                              |
| Berendsen et al. (2017)        | DASH         | Cohort       | Older American women               | Long-term adherence to the DASH diet is associated with better average cognitive function but not with change in cognitive function over the follow-up period | 6 years                          | [69]                              |
| Haring et al. (2016)           | MeDi         | Cohort       | Older American women               | No association between aMED and DASH scores and incidence of MCI or dementia in older women generally or in those with hypertension | 9.1 years                        | [70]                              |
| Smith et al. (2010)            | DASH         | RCT (ENCORE) | Overweight and sedentary individuals (USA) | Slight improvements in psychomotor speed after the intervention with the DASH diet | 4 months                         | [71]                              |
| McEvoy CT et al. (2017)        | MeDi         | Cross-sectional | Older U.S. adults                 | Greater adherence to the MeDi and MIND diet is independently associated with better cognitive function and lower risk of cognitive impairment | NA                               | J Am Geriatr Soc. (2017) 65:1857–1862 |
such as the mean age of subjects, the duration of follow-up, and the high number of neuropsychological tests used for the diagnosis of MCI and/or AD.

2.2. Randomized Controlled Trials (RCTs). Only few RCTs (PREDIMED, MedLey, and NU-AGE) have assessed the effects of a Mediterranean dietary pattern on cognition in older adults both in Mediterranean and non-Mediterranean countries (see Table 2).

The first RCT to evaluate the effects of long-term MeDi intervention on cognitive function and to shed some light on the role of dietary patterns in counteracting the neurodegenerative process was carried out on a subcohort of the well-known multicenter PREDIMED trial, which was a milestone in establishing the strong preventive role of the MeDi in individuals at a high cardiovascular risk [42]. The nutritional intervention of PREDIMED consisted in a typical MeDi supplemented with extravirgin olive oil or mixed nuts (foods with antioxidant and anti-inflammatory properties) compared to a control low-fat diet. Martinez-Lapiscina and colleagues [43] enrolled 522 subjects and assessed the overall cognitive performance at study completion alone, after 6.5 years. They reported a significant difference in mean Mini-Mental State Examination (MMSE) and Clock Drawing Test (CDT) scores in both intervention groups versus the low-fat control group. There were two main limitations in this study: (1) the lack of evaluation of cognitive performance at the beginning of the study, which did not allow to evaluate changes in cognitive functions over time and (2) the insufficient statistical power to demonstrate a protective effect of MeDi on dementia development, given the small number of total incident cases that were observed during the follow-up.

After a few years, Valls-Pedret et al. [44] published the first MeDi intervention trial demonstrating a positive effect on cognition of the MeDi supplemented with either nuts or extravirgin olive oil. In this PREDIMED substudy, cognitive performance was evaluated both pre- and postintervention, thus enabling the researchers to detect any significant cognitive improvement in the participants allocated to the MeDi intervention groups, who were assessed after a median of 4.1 years.

The MedLey study was the first RCT conducted in older non-Mediterranean adults. A total of 137 subjects were randomly assigned to either a MeDi or a control diet (their usual diet) for six months. This study did not find any significant beneficial effects of a MeDi intervention on cognitive functions (executive functioning, speed of processing, memory visual-spatial ability, and overall age-related cognitive performance) among healthy older adults, perhaps because of the short duration of the intervention, the relatively limited number of participants, or the “Australianization” of the MeDi (i.e., based on the Australian foods and habits, rather than on the traditional MeDi), resulting in smaller nutritional intervention differences between the intervention groups and the control group [45].

The NU-AGE trial (NCT01754012), a recent 1-year multicenter RCT, was carried out in both Mediterranean (including Italy) and non-Mediterranean European countries and allocated a total of 1,279 healthy older adults to two parallel groups. The intervention group followed the NU-AGE diet, which consisted of a culturally adapted and individually tailored Mediterranean-like diet on the basis of the specific dietary recommendations for older adults in the various countries involved in the study. One year later, at the end of the study, all participants showed improvements in their cognitive performance but the differences between the two groups did not reach statistical significance [46]. Nonetheless, the authors highlighted that the participants in the intervention group with the highest adherence to the NU-AGE diet showed a significant improvement in episodic memory, the impairment of which is a core feature of AD [47].

To date, results from RCTs are mostly nonsignificant, with small effect sizes and little or no benefit of the MeDi for incident cognitive impairment or dementia, as also documented by a recent systematic review of RCTs by Radd-Vagenas et al. [48]. RCTs with a longer duration and higher number of participants are needed to establish whether adherence to the MeDi can help prevent (or delay) the onset of AD and dementia.

2.3. Mediterranean Diet and Brain Imaging. AD is a neurodegenerative disease characterized by typical changes in the brain that can be detected by a variety of imaging modalities, including structural and functional Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET). In recent years, cross-sectional and longitudinal studies have shown the relationship between lifestyle and dietary habits and the morphological, structural, functional, and metabolic modifications of the brain regions that undergo neurodegeneration in the preclinical and clinical phases of AD.

2.3.1. Mediterranean Diet and Structural Brain Modifications. Growing evidence, derived mainly from MRI studies, suggests an association between higher MeDi adherence and preservation of brain structures, in particular in the so-called “Regions-of-Interest” (ROIs) which are vulnerable to the neurodegenerative changes typical of AD. Higher MeDi adherence was associated with a significantly greater thickness of 3 ROIs (orbitofrontal cortex, entorhinal cortex, and posterior cingulate cortex of the left hemisphere) in a cross-sectional study performed on an American population of cognitively normal middle-aged participants [49]. Similar findings were reported by two other cross-sectional American studies in which the greatest benefit in terms of brain structure preservation was attributed to the higher intake of fish and legumes and lower intake of meat [50, 51]. More recently, Karstens et al. found that higher adherence to the Mediterranean pattern was associated with better learning and memory performance and larger bilateral dentate gyrus volumes after adjusting for a number of confounding factors [52].

Conversely, several longitudinal studies reported a negative effect on brain structures related to lower adherence to the MeDi [53] or adherence to an unhealthy Western dietary pattern [54], while a Swedish longitudinal study including 194 cognitively healthy elderly individuals found no
association between the total MeDi score and the brain volumes perhaps due to the intrinsic limitations of the study design [55].

In conclusion, gray matter atrophy and reduced cortical thickness in the medial temporal lobe are a typical early feature of AD, and the association of MeDi adherence with greater gray matter volumes in AD regions may indicate some direct involvement of this type of dietary pattern in preventing or slowing the neurodegeneration and the consequent neuronal loss that is typical of this disease. More recently, Pelletier and colleagues reported a positive association between higher MeDi adherence and a general pattern of preserved white matter microstructure with no relation to gray matter volumes, suggestive of alternative mechanisms partly independent of AD-related neurodegeneration, possibly including vascular pathways [56]. The beneficial effect of the MeDi on vascular risk factors (e.g., lipid profile, blood pressure, insulin resistance, adiposity, inflammation, and oxidative stress) is in fact well established [57–60].

2.3.2. Mediterranean Diet and Functional Brain Modifications. The AD brain is characterized by several metabolic changes that can also be found in other neurodegenerative diseases and in normally aging brains and represent nonspecific biomarkers of impairment of neuronal activity and synaptic transmission. These metabolic and functional modifications can be detected by PET, in particular, fluoro-deoxyglucose- (FDG-) PET and Pittsburgh Compound B- (PiB-) PET which allow us to evaluate changes in cerebral glucose metabolism (an indicator of neuronal network activity) and the degree of beta-amyloid (Aβ) deposition in brain regions known to be involved in AD. Studies concerning the association between MeDi adherence (and in general, adherence to a healthy dietary pattern) and functional neuroimaging outcomes are limited.

Two cross-sectional studies in the American population found an association between higher adherence to a MeDi pattern and lower 11C-PiB PET scan measurements of Aβ deposition as well as higher glucose metabolism as observed by FDG-PET scans [61, 62]. Higher MeDi adherence was also associated with reduced cerebral Aβ accumulation over time (up to 3 years) in a longitudinal study performed by Rainey-Smith et al. on older Australian adults classified as “Aβ accumulators” and thus considered to be on the way to AD [63]. However, the association between the Mediterranean dietary pattern and amyloid deposition or cortical thickness has not been confirmed in all reported studies. In a longitudinal study that involved 70 middle-aged participants living in New York, lower adherence to a Mediterranean-style diet was associated with faster decline in glucose metabolism in the posterior cingulate cortex (an early site of cerebral glucose utilization decline in AD and a well-established predictor of the progression from mild cognitive impairment to AD) and marginally in the frontal cortex, although without any significant changes in amyloid deposition or cortical thickness [64].

In conclusion, the neuroprotective effects of the MeDi may also lie in its ability to preserve brain metabolic activity and glucose metabolism in key brain regions for AD.

3. DASH Diet and AD Prevention

The DASH diet, which stands for Dietary Approaches to Stop Hypertension, promoted by the National Heart, Lung, and Blood Institute (NHLBI), is a dietary pattern that was first developed to identify dietary factors affecting blood pressure. The DASH diet is high in fruits, vegetables, nuts, whole-cereal products, low-fat dairy products, fish, and poultry, all of which are rich in blood-pressure-deflating nutrients like potassium, calcium, “lean proteins,” minerals, and fiber (see Table 1). DASH also discourages the intake of foods like red and processed meats, full-fat dairy foods, and tropical oils, as well as sugar-sweetened beverages and sweets; therefore, it is designed to be low in sodium, saturated fats, total fats, and cholesterol [65]. This type of dietary pattern has been shown to protect against many cardiovascular risk factors that play a role in the development of dementia and AD (such as high blood pressure or LDL cholesterol), at least in part by modulating the pathological processes that characterize the physiopathology of AD (oxidative stress, inflammation, and insulin resistance) [66]. DASH and MeDi share many food components (i.e., whole-grains, vegetables, and nuts), but there are also some differences, such as the frequency of consumption of low-fat dairy products (moderate-to-high intake and low consumption, respectively).

To date, only a few studies have evaluated the potential effects of the DASH diet on cognitive functions or on the prevention of AD and other types of dementia.

3.1. Epidemiological Evidence. As already stated with regard to the Mediterranean diet, higher adherence to the DASH diet has been associated with slower rates of cognitive decline and reduced incidence of AD [67–69] (see Table 2).

In the study of Morris and colleagues [68], only the highest tertiles of the DASH and MeDi scores were significantly associated with a lower rate of incident AD (39% and 54% reduction, respectively).

Berendsen et al. [69] found a positive association between long-term adherence to the DASH diet and better cognitive function in older American women participating in the Nurses’ Health Study, regardless of apolipoprotein E ε4 allele status, but not with slower cognitive decline during the course of follow-up (6 years). On the contrary, another study which included only older American women, the Women’s Health Initiative Memory Study (WHIMS), reported that DASH scores were not associated with incidence of MCI or dementia [70].

3.2. RCTs. The only RCT which examined the potential effects of the DASH diet on neurocognitive functioning was performed some years ago by Smith and colleagues [71] (see Table 2). In the ENCORE trial 124 subjects with high blood pressure were randomized to the DASH diet alone or DASH combined with a behavioral weight management program including exercise and calorie restriction (CR), or to a “usual diet” control group. After 4 months of intervention, psychomotor function improved in both DASH interventions regardless of weight strategies, but only the group which underwent a combination of DASH diet with aerobic
exercise and calorie restriction showed a significant improvement in neurocognitive function (executive memory and learning functions) [71].

4. MIND Diet and AD Prevention

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) was developed some years ago by researchers at Rush University Medical Center in Chicago, IL, and Harvard School of Public Health in Boston, MA, as a hybrid of the Mediterranean-DASH diet. The MIND diet is based on 10 brain-healthy foods (leafy green vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil, and wine) and 5 unhealthy foods (red meats, butter and stick margarines, cheese, pastries and sweets, and fried or fast food), all of which have a strong scientific rationale in the field of nutritional prevention of dementia [72, 73] (see Table 1). Compared to the MeDi, the MIND diet includes a lower consumption of fish, usually 1 serving/week, as does the DASH diet. This relatively low level of fish consumption reflects the findings of prospective epidemiological studies, such as the Rotterdam study which examined the role of fish intake in AD prevention [74–76]. As stated above, leafy green vegetables, in addition to other types of vegetables, are recommended on the basis of several epidemiological studies that reported a significant association between high consumption and slower cognitive decline [77, 78]. Berries represent a separate category in the MIND diet, reflecting strong associations between the consumption of this type of fruit and brain health. Many studies have documented the beneficial effects of various types of berries, including potent anti-inflammatory and antioxidant activity in cell models of neurotoxicity [79, 80]. Moreover, in vivo studies on animals supplemented with a berry-enriched diet reported improvements in motor coordination, cognitive performance (spatial memory, learning), hippocampal plasticity, and age-related neuronal loss [81–83]. A unique characteristic of berries is the high content of polyphenols such as flavonoids (anthocyanins and flavonols), which are the main compounds responsible for the antioxidant and anti-inflammatory characteristics of berries [84, 85]. The association between a high intake of berries and flavonoids and slower rates of cognitive decline have also been reported in humans [86], confirming the results that were observed in experimental studies.

4.1. Epidemiological Evidence. Two papers published by Morris and other researchers from Rush University (Chicago, IL, USA) clearly demonstrated the superiority of the MIND diet compared to both the MeDi and the DASH diet in slowing the rates of cognitive decline [28] and in reducing the risk of incident AD or dementia [68]. The MIND diet score was linearly and statistically significantly associated with a lower risk of developing AD (see Table 2). Subjects in both the middle and the highest tertiles of MIND scores had a statistically significant reduction in AD rates compared to those in the lowest tertile, while only those in the highest tertile of MeDi and DASH scores were significantly associated with a lower rate of incident AD [68].

To date, no randomized controlled trials have been published evaluating the effect of the MIND diet on the prevention of AD, but there are two ongoing studies testing the effects of an intervention with the MIND diet on cognitive decline and brain neurodegeneration, the results of which will be reported in the coming years (http://www.clinicaltrials.gov/NCT02817074, http://www.clinicaltrials.gov/NCT03585907).

5. Dietary Patterns and the Brain: The Underlying Mechanisms

The clinical evidence that has been collected in recent years suggests that the dietary patterns described above, namely, the Mediterranean diet, the DASH diet, and more recently the MIND diet, are able to modify the natural history of neurodegenerative pathologies, in particular AD, thereby preventing their development or slowing down their progression. But what is the basis of the favorable neuroprotective effects of these dietary patterns? What are the links between diet and the human brain? Are there any other factors that modulate the effects of diet on the brain?

The strength of these dietary approaches lies in their multifactorial composition. In fact, nutrient-dense foods can interact with each other with potentially synergistic effects on different metabolic and cellular signaling pathways, leading to neuroprotection and maintaining brain health. But there are considerable methodological difficulties in conducting *in vitro* and *in vivo* studies to document the effects of such dietary patterns on the brain, due to the intrinsic complexity of a whole diet, the micro- and macronutrient composition, the importance of food cooking methods, and at least for the Mediterranean diet, the undeniable aspect of conviviality that characterizes this dietary lifestyle. All of these aspects are obviously difficult to reproduce and quantify in experimental models.

To date, the precise mechanisms underlying the neuroprotective benefits associated with the MeDi and the other dietary patterns are not fully understood, even if it is widely accepted that they play a role in counteracting several biological processes implicated in the pathogenesis of AD, e.g., oxidative stress, neuroinflammation, neurovascular dysfunctions and hypoperfusion, disruption of the gut-brain axis, and impairment of hippocampal neurogenesis. It is also possible that these dietary patterns might influence Aβ or Tau metabolism, even if evidence concerning these mechanisms were largely obtained from animal studies and require further assessment and confirmation [87, 88]. At a systemic level, they can also indirectly improve cognition by reducing cardiovascular risk factors such as lipid levels, blood glucose, and blood pressure [89, 90].

5.1. Neurovascular Dysfunctions. Cerebral blood flow regulation is essential for normal brain function. AD is known to be associated with early neurovascular dysfunction and damage to small arteries, arterioles, and brain capillaries via both Aβ-independent (such as hypoxia and/or ischemia) and Aβ-dependent pathways (Aβ angiopathy). These changes, together with the loss of integrity of the blood-brain barrier
(BBB), play a part in disease pathogenesis and lead to neuro-
nal and synaptic dysfunction, neurodegeneration, and cogni-
tive impairment [91, 92]. Several risk factors can contribute
to neurovascular dysfunction, for example, genetic factors
(APOE4 genotype), vascular factors (hypertension and diabe-
etes mellitus), and environmental factors (for example, 
pollution). Hypertension is a well-known risk factor for
AD, and animal studies have shown impairment in
acetylcholine-dependent and endothelium-dependent vaso-
dilation with a consequent reduction of cerebral blood flow
after several stimuli [93]. Chronically elevated blood pressure
can also enhance Aβ-induced neurovascular dysfunction,
promote β-secretase activity, and lead to amyloidogenic pro-
cessing of the amyloid precursor protein (APP), with further
damage to small arteries and arterioles, rupture of the vessel
wall, and microhemorrhages [93].

Hence, the importance and the possible preventive and
neuroprotective role of a diet such as the DASH diet, which
thanks to its reduced content of sugars, sweets/pastries, and
sodium can act positively on some of the triggers of neuro-
vascular dysregulation (hypertension and hyperglycemia/in-
sulin resistance) [94]. In addition to limiting the intake of
such detrimental foods and nutrients, increasing evidence
supports the regular consumption of flavonoid-rich foods,
which are associated with better endothelial function, tissue
perfusion, and enhanced neuronal viability. For example,
the flavonoids contained in cocoa powder (mainly epicate-
chin) act directly on the endothelium of brain vessels
enhancing the activity of endothelial nitric oxide synthase
(eNOS) and thereby increasing vasodilatation and cerebro-
vascular perfusion [95].

5.2. Oxidative Stress. The imbalance between the production
of reactive oxygen species (ROS) and antioxidant defenses
has been shown to contribute significantly to the pathogene-
sis and progression of AD [96] and is known to be associated
with oxidative damage to DNA, proteins, and lipids com-
ponents of neurons and with subsequently impaired synaptic
activity and neuronal apoptotic death [96]. Several antioxi-
dant compounds can modulate signaling cascades involving
protein and lipid kinases and downstream partners, resulting
in the inhibition of neuronal apoptosis induced by toxic
products such as ROS [97].

All three dietary patterns discussed in this review are
exceptionally rich in foods with a high antioxidant content.
Leafy green vegetables and other vegetables, citrus fruits,
nuts, red wine, berries, and olive oil all provide a large
amount of vitamins, polyphenols, and carotenoids that can
prevent and/or repair the damage caused by free radicals
(e.g., superoxide, O₂− and nitric oxide, NO) and by proin-
flammatroy cytokines (e.g., IL-1β and TNF-α) that are pro-
duced by activated microglial cells in response to oxidative
damage. One of the main components of the Mediterranean
diet, as well as the main source of fat in this diet, is extravirgin
olive oil (EVOO), which contains mainly oleic acid and to a
lesser extent linoleic acid. In addition, EVOO contains hun-
dreds of bioactive compounds including triterpenes (i.e.,
squalene), biophenols (hydroxytyrosol, tyrosol, and oleu-
pein), pigments (carotenoids, xanthophylls, and lutein), and
vitamin E (tocopherols), whose beneficial effects have been
shown in several studies [98, 99]. The low (and nontoxic)
level of oxidized forms of EVOO polyphenols in plasma
and tissues can activate the Nrf2 pathway and other adaptive
stress response systems leading to the upregulation of
the endogenous antioxidant and detoxification enzymes
and thus rendering the cells “protected” against more dangerous
and chronic oxidative stress stimuli (hormesis) [100]. Recent
studies have shown that hydroxytyrosol, oleuropein, and
oleacein can activate the Nrf2 pathway both in vitro and
in vivo [101, 102].

5.3. Neuroinflammation. Microglial cells are the first and
most important immune defense of the brain. While proper
microglial function is essentially required for scavenging pla-
ques, damaged molecules, and infectious agents, microglial
hyperactivation is a well-established hallmark of neuroin-
flammation and one of the main actors in AD pathogenesis
[103]. In the AD process, the excessive production and
deposition of the Aβ peptides trigger an innate immune
response and consequently an aberrant production of
ROS, proinflammatory cytokine, and chemokine secretion,
and degradation of the neuroprotective factors, such as
retinoids, involved in promoting adult neurogenesis in the
hippocampus [104, 105]. This chronic inflammatory
response contributes to disease progression and severity,
further boosts Aβ production and deposition, and ultimately
leads to neuronal death [106, 107]. Several exogenous or
endogenous factors can exacerbate the innate immune
response mounted by Aβ-exposed microglia, including
genetic factors (for example, TREM2 mutation [108] and
APOE4 genotype [109]), traumatic brain injuries, diabetes
[110], and obesity [111]. Diet is known to modulate the
immune system, and a healthy diet rich in nutrients and bio-
active compounds with anti-inflammatory and antioxidant
properties can help to counteract the neuroinflammatory
process.

Fruits, vegetables, whole grains, and other plant foods
provide a wide range of phytochemicals, vitamins, min-
erals, and fibers with well-established antioxidant anti-
inflammatory properties. Phytochemicals are bioactive
plant-derived compounds that include various subgroups
(phenolics, alkaldoids, organosulfur compounds, phytos-
terols, and carotenoids). One example is Ferulic Acid
(FA), an antioxidant with free radical scavenging activity
but also antiamyloidogenic properties, as documented in a
number of in vitro [112, 113] and in vivo studies [114, 115]
in transgenic mouse models of AD. Resveratrol, another phe-
nolic compound, is mainly found in the skin of many edible
plant species, such as mulberries, grapes, peanuts, and pome-
granates, as well as in red wine [116]. There are a multitude of
actions that have been attributed to resveratrol: inhibition of
Tau and Aβ plaque synthesis [117, 118], downregulation of
prooxidative stress proteins [119] and increased levels of
heme-oxigenase-1 (HO-1) [120] and SIRT-1, and inhibition
of neuroinflammation [121, 122].

Long chain omega-3 polyunsaturated fatty acids (ω-3
PUFAs) are also important [123]. Docosahexaenoic acid
(DHA) and Eicosapentaenoic Acid (EPA), two main types
of \( n - 3 \) PUFAs, are abundantly present in seafood and fish oil. *In vitro* experiments showed that EPA and/or DHA administration decreases the expression of proinflammatory factors, such as inducible NO synthase (iNOS), cyclooxygenase (COX) 2, interleukin-1β (IL-1β), IL-6, Tumor Necrosis Factor-α (TNF-α), and Nuclear Factor-κB (NF-κB), and promotes the expression of anti-inflammatory cytokines. In rodents, the consumption of a diet enriched in \( n - 3 \) PUFAs prevents the dysregulation of cytokine production in hippocampal microglial cells in response to Lipopolysaccharide (LPS) [124], reduces hippocampal \( \beta \)-amyloid plaque density by modifying the fibrillar/prefibrillar \( \beta \)-amyloid oligomer ratio (the former are less toxic), and leads to mild improvements in the behavioral testing of the transgenic APP/PS1 rodent model of AD [125]. Moreover, dietary omega-3 and omega-6 PUFA and monounsaturated fatty acid (MUFA) intake may influence the membrane fluidity and enzyme activity in neurons, leading to the potential modulation of brain structures and functions [126].

### 5.4. Gut Microbiota Dysbiosis

The human gut microbiota includes approximately \( 10^{14} \) microbes belonging to hundreds of different species and to five predominant phyla and is mainly composed of two phyla: *Firmicutes* (60-80%) and *Bacteroides* (20-30%), followed by *Actinobacteria, Verrucomicrobia,* and *Proteobacteria* [127, 128]. The gut microbiota plays a crucial role in human health but also in a variety of human diseases, at least in part through the production and release of numerous small molecules like vitamins (folate, vitamin B12), amino acids (tryptophan), and short chain fatty acids (SCFAs). Some of these bioactive substances (SCFAs, catecholamines, neurotransmitters, neuropeptides, and miRNAs) are transported into the blood and can cross the BBB thus affecting the central nervous system (CNS). Additionally, the CNS communicates with the gut through efferent autonomic pathways, thus modulating many gut functions like permeability, mucus secretion, motility, and immunity. This bidirectional communication between the gastrointestinal system and the CNS is called the gut-brain axis [129].

A healthy microbiota is fundamental for the metabolization of such dietary nutrients (like polyphenols) which require transformation to become active compounds having beneficial effects on the brain. Curcumin metabolites produced by the microbiota can exert anti-inflammatory and neuroprotective effects [130], including interesting positive effects on Tau pathology [131].

The composition of human gut microbiota is dynamic and can be shaped by various factors such as the type of childhood and newborn feeding, diet, use of drugs, or pre/probiotics, as well as age, sex, and geographical area. The Mediterranean diet, which is rich in plant-based foods, fibers, and monounsaturated fats, is considered the gold standard for gut health and promotes the diversification of the microbiota [132]. Conversely, the typical Western diet, which is made up of low dietary fiber and high animal protein and saturated fat, is associated with a negative change in the gut microbiota composition (dysbiosis), as documented by an increase in *Firmicutes* and Gram-negative bacteria [133]. As previously mentioned, age is another important modulating factor of human gut microbiota composition. Several reviews analyzed gut microbiota age-related changes and the potential relationships between gut dysbiosis and inflamming [134–136].

During aging, the gut undergoes a continuous and profound remodeling, as a result of modification of lifestyle, nutrition, behavior, immunosenescence (a decline in an immune system functioning), and inflamming (the chronic low-grade inflammatory status typical of the elderly). Moreover, aging-associated alterations in gut physiology (i.e., gastric motility disorders, hypochlorhydria, and degenerative changes in the enteric nervous system) have profound effects on the diversity, composition, and functional features of intestinal microbiome [137]. Several authors reported a reduction in the microbiota diversity and a greater interindividual variation in microbiota composition in elderly people (>65 years of age), with reduced numbers of *Bifidobacteria, Firmicutes, Faecalibacterium prausnitzii,* and *Clostridium* cluster XIV and increased numbers of *Bacteroidetes* and *Enterobacteriaceae* even if with some differences between various populations [138–140].

The inflammatory process can affect the gut environment by enhancing the level of aerobicism and the production of ROS that inactivate the strict anaerobic *Firmicutes*, while allowing the growth of facultative aerobes (i.e., *Enterobacteriaceae, Enterococcaceae,* and *Staphylococcaceae*). These so-called “pathobionts” can survive in the presence of oxygen, so they can prosper in an inflamed gut, and in turn, they promote a proinflammatory profile (increase of II-6 and II-8 levels) and compromise the host immune homeostasis, in a sort of self-sustaining loop [141].

Gut dysbiosis has been linked to the development of several health problems, including psychiatric or neurodegenerative diseases. An increasing body of evidence suggests that alterations to the gut microbiota can play a role in the pathogenesis of AD. Dysbiosis can amplify neuroinflammation and accelerate neurodegeneration, and this brain-gut microbiota axis can actually be modulated by dietary factors. In aging mice, AD-like symptoms were associated with increased gut permeability, inflammation, and a microbiome profile similar to that of murine inflammatory bowel disease [142]. Experimental mice models of AD showed a decrease in microbiota diversity with age, an increased number of taxa with proinflammatory and pathobionts (i.e., *Odoribacter, Helicobacter,* and *Sutterella*), and impaired production of SCFAs [143, 144]. All these modifications can be worsened by feeding transgenic mice a high-fat diet [145]. Moreover, gut microbiota dysbiosis in mouse models of dementia may be involved in neuroinflammation, reduced expression of hippocampal brain-derived neurotrophic factor (BDNF) and other signaling molecules, and amyloid deposition [146–148]. Conversely, administering probiotics to rodents with artificially induced AD led to an improvement in cognitive functions, especially spatial working tasks, less neuron degeneration and lower levels of proinflammatory cytokines [149–151], microglial activation and oxidative stress, improved mitochondrial dysfunction, and restoration of hippocampal plasticity [152].
In conclusion, long-term dietary habits may influence gut microbiota biodiversity, its functions, and the secretion of metabolites that, once absorbed in the systemic circulation, can modulate neural function and possibly enhance neuroinflammation, neuronal apoptosis, and β-amyloid deposition [153]. The modulation of gut microbiota by adopting and maintaining a healthy diet can be an effective strategy in AD prevention. However, the transposition of these results into humans is still premature given the absence of clinical studies, especially in middle-aged or older patients at risk of developing AD or with MCI.

5.5. Adult Hippocampal Neurogenesis. The hippocampus is the key brain region for learning and memory. Incorporation of new neurons into the granular cell layer of the dentate gyrus of the hippocampus is substantial throughout life, and adult neurogenesis has important implications in maintaining cognitive functions [154]. This brain area is highly involved in the process of neurodegeneration that is typical of AD. Numerous studies have documented an impairment of neurogenesis and relative memory loss as well as cognitive dysfunction in mouse models of AD even in the very early stages of the disease [155]. Environmental factors such as exercise and calorie restriction (see the specific chapter below) have been shown to increase adult hippocampal neurogenesis, while low-grade inflammation and oxidative stress seem to decrease it [156]. Hippocampal neurogenesis is regulated by several signaling pathways such as presenilin-1, Notch 1, soluble amyloid precursor protein, CREB, and β-catenin and is also mediated by neurotrophins such as BDNF. A poor diet can have detrimental effects on hippocampal neurogenesis. Diets that are rich in saturated fats/trans fatty acids and refined sugars, like Western diets, reduce the levels of BDNF and contribute to an increased production of ROS and proinflammatory cytokines, leading to neurodegeneration and learning and memory impairment [157]. On the contrary, dietary patterns based on foods that are rich in omega-3 fatty acids, flavonoids, and other antioxidants stimulate neurogenesis, reduce oxidative activity, and downregulate proinflammatory processes [158, 159].

6. Intermittent Fasting: A New Dietary Pattern for AD?

Aging is one of the main risk factors for AD. The aging brain and the “AD-Brain” share many characteristics, both at an anatomical and at a cellular/molecular level [160]. Indeed, many of the principal hallmarks of aging (e.g., oxidative stress, mitochondrial dysfunction, accumulation of oxidatively damaged molecules, impaired autophagy, disruption of Ca\(^{2+}\) homeostasis, aberrant neuronal network excitability, and neuroinflammation) have also been documented in AD, and these changes may promote amyloidogenic APP processing and Tau pathology and vice versa [161, 162].

Over the last 30 years, emerging evidence has shown the beneficial effects of fasting and CR as alternative or complementary strategies to other lifestyle interventions (e.g., physical activity) and to pharmacological therapies in AD prevention and treatment.

During the first 10-14 hours of fasting, the main source of energy for neurons is made up of glucose derived from the degradation of the liver glycogen store. Then, a “metabolic switch” occurs, characterized by liver production of Ketone Bodies (KBs) like β-hydroxybutyrate (BHB) and acetocetate (AcAc) from the fatty acids released by adipose tissue in response to fasting; in this second phase, KBs represent the main fuel for neurons [163]. Besides this “metabolic switch,” fasting can enhance a complex series of adaptive responses to limited food availability, which are to some degree, the same endogenous stress-response systems activated by foods that are rich in polyphenols and other bioactive compounds (as described above) [164].

In prokaryotes, laboratory animals and humans, a daily 20-40% CR, can protect against aging, oxidative stress, and neurodegenerative disorders and can also extend longevity [165, 166], but the feasibility and long-term tolerability are low, especially in patients with AD. Other studies have shown the same positive results by alternating normal diets with more feasible regimens, such as intermittent fasting (IF) or periodic fasting (PF) that are short periods of fasting which differ from each other with regard to duration and frequency. The best-characterized form of fasting that has been studied both in animal models and in humans is Alternate-Day Fasting (ADF), which implies fasting every other day [167, 168] or a 70% CR every other day [169, 170] or even 2 consecutive days of Very Low-Calorie Diet (VLCD) per week [171]. Upcoming alternatives are the so-called Fasting-Mimicking Diets (FMDs), characterized by periodic cycles of plant-based dietary programs lasting from 3 to 7 days, that are low in protein and in overall caloric intake but contain all the necessary micronutrients [172, 173]. Regardless of how fasting has been applied in these studies, it should be emphasized that it is different from starvation, which leads to chronic insufficiency of nutrients, malnutrition, and ultimately degeneration and death.

6.1. Why Is Fasting Good for the Brain?

6.1.1. Looking Briefly at the Molecular Mechanisms. Fasting substantially modifies the neurochemistry and the activity of the neuronal network especially in several brain regions such as the hippocampus, the striatum, the hypothalamus, and the brainstem. At the molecular level, a variety of signaling pathways have been identified that mediate the structural (increased synaptic density, neurogenesis) and functional (Long-Term Potentiation, LTP) adaptive responses of neuronal circuits to nutrient restriction, in particular low glucose and amino acid levels [174] (see Figure 1). Both increased excitatory synaptic activity and neurotrophic factors (BDNF and fibroblast growth factor 2) lead to the activation of multiple kinases, including phosphatidylinositol 3-kinase (PI-3K), serine/threonine-protein kinase (AKT), Mitogen-Activated Protein Kinases (MAPKs) and Ca\(^{2+}\)/calmodulin-dependent kinase (CaMK), nitric oxide synthase (NOS), and calcineurin, which all converge on several transcription factors like cAMP-Responsive Element-Binding protein (CREB), nuclear regulatory factor 2 (Nrf2), and NF-κB [166, 175]. These transcription factors, which include BDNF...
[166], sirtuin-3 (SIRT3) [176], peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) [177], and heat-shock protein 70 (HSP-70), induce the expression of genes and proteins involved in enhancing neuroplasticity and stress resistance [178]. Part of the benefits of CR/fasting seems to be related to protein restriction and reduced IGF1/insulin signaling. During protein restriction, mTOR, and in particular complex 1 (mTORC1), is repressed, thus allowing the cell to enter a “conservative” energy mode to inhibit protein and lipid synthesis and enhanced autophagy [179, 180].

6.2. Fasting and AD

6.2.1. Preclinical Studies. Most of the scientific evidence regarding IF or PF regimens and AD treatment derives from studies on laboratory animals. In rodents, several studies showed that fasting and FMDs are able to improve motor and cognitive functions, in particular hippocampal-dependent tasks like learning and memory [172, 181–183]. Moreover, IF has been associated with reduced oxidative stress and brain structural improvements such as increased thickness of the CA1 pyramidal cell layer and higher expression of the dendritic protein drebrin in the hippocampus [184].

IF and ketogenic diets can also modify neuronal network activity and synaptic plasticity. The neurons of rodents on an ADF regimen are more resistant to excitotoxin-induced degeneration of hippocampal neurons with kainic acid and perform better in water-maze learning and memory tasks [167, 185]. IF and/or regular physical activity can also prevent age-related deficits in LTP, a common cellular manifestation of learning and memory occurring in response to repetitive stimulation of synapses [186–189]. Other research groups also documented a role of CR/IF regimens in reducing Aβ deposition and Tau phosphorylation in the hippocampus and cerebral cortex of a transgenic mouse model of AD [190–194]. Recently, Zhang et al. highlighted the role of IF (and in particular BHB) in restoring the polarity of AQP4, a protein channel involved in Aβ clearance, that is often impaired in AD, thereby providing another possible explanation for the positive role of ADF in improving cognitive functions and protecting against Aβ pathology [195].

Lastly, IF, with or without exercise, stimulates the growth and differentiation of new neurons into granule neurons in the hippocampal dentate gyrus, i.e., adult hippocampal neurogenesis, and the creation of synaptic connections (dendritic spine growth and synaptogenesis) among themselves or with other neurons from other brain regions such as the entorhinal cortex, basal forebrain, and amygdala [172, 196, 197].

6.2.2. CR and IF in Humans. Several human studies have shown that the decrease in energy intake can reduce visceral fat (while preserving lean mass), improve glucose and lipid metabolism, and reduce blood pressure and blood biomarkers of inflammation (C-reactive protein and proinflammatory cytokines) [171, 198, 199]. All these beneficial effects may translate into a lower risk of cardiovascular disease, diabetes, and also neurodegenerative diseases such as AD.

Currently, no studies have been conducted on protein and/or calorie restriction in human subjects with established AD, but some authors have underlined the potential role of protein restriction against the aging process and aging-related chronic diseases [200]. However, it is important to properly time the application of protein restriction during life since the beneficial effects seem to be lost in people over 65 years of age [201].
Short periods of CR are able to improve cognitive function (verbal memory) in elderly subjects [202], and 30 days of a low glycemic diet in patients with MCI resulted in an improvement in delayed visual memory, cerebrospinal fluid biomarkers of Aβ metabolism, and brain bioenergetics [203], but it is hard to believe that severe restrictions could be tolerated for long periods, especially in elderly subjects affected by neurodegenerative diseases. IF regimens or FMD cycles every 1-2 months seem to be more feasible and tolerable in clinical practice. Recent pilot clinical trials applying such dietary regimens in healthy subjects and in patients with cancer, diabetes, and multiple sclerosis have been developed and have shown promising results [172, 173, 204], while several trials are still ongoing (https://clinicaltrials.gov/NCT03595540, https://clinicaltrials.gov/NCT03700437, and https://clinicaltrials.gov/NCT03811587).

The next step will be to demonstrate whether the various types of fasting (including ADF and FMD) have neuroprotective and regenerative effects in patients with early-stage AD. Our group will carry out a pilot study in an effort to assess the safety and feasibility of monthly cycles of an FMD diet in patients with a diagnosis of MCI or early AD.

In conclusion, emerging evidence on the effects of fasting on animal models of aging brain and neurodegenerative diseases is promising, but the applicability and potential efficacy of these dietary regimens in humans, and in particular in patients with MCI or AD, are yet to be established.

7. Conclusions

To date, it is not possible to establish with certainty a causal relationship between diet and the development of AD because there are still many confounding factors and biases:

1. There may be confounding factors that contribute to increasing or reducing the risk of AD (physical activity, cardiovascular risk factors, and apoE4 status)

2. There is broad heterogeneity among the characteristics of the studies, such as the mean age of the study subjects (50-85 years), diverse geographic settings (differences in the dietary patterns or in the environmental factors in Mediterranean or non-Mediterranean regions), sample size, study designs (cross-sectional, prospective, case-control, and RCTs), and length of follow-up

3. Several different methods have been used for evaluating eating habits (different questionnaires, food diary, and 24-hour dietary recall)

4. There is broad heterogeneity in the criteria used for the evaluation of cognitive performance and diagnosis of AD (single neuropsychological tests or neuropsychological batteries)

5. None of the studies take into account the possible modifications in an individual's eating habits over the course of one's life as related to psychological (e.g., depression), physiological (e.g., difficulty in chewing and modification of appetite), or socioeconomic changes (e.g., social isolation, financial difficulties, and lack of family support)

6. There is broad heterogeneity in the study outcomes (AD incidence or prevalence, worsening of the overall cognitive performance or even of some specific cognitive domains)

Currently available drugs (cholinesterase inhibitors and memantine) are able to partially control the symptoms but do not slow down the progression of AD. Therefore, there is an urgent need for new complementary therapeutic approaches, and in this context, the modulation of dietary habits and well-conducted nutritional interventions could be a useful and inexpensive tool.

Conflicts of Interest

The authors have no relevant disclosures of potential conflicts of interest.

References

[1] Alzheimer's Disease International, ”World Alzheimer report 2015,” The Global Economic Impact of Dementia, 2015.

[2] M. D. M. Haag, A. Hofman, P. J. Koudstaal, B. H. C. Stricker, and M. M. B. Breteler, ”Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 80, no. 1, pp. 13–17, 2009.

[3] E. M. van der Beek and P. J. G. H. Kamphuis, ”The potential role of nutritional components in the management of Alzheimer’s disease,” European Journal of Pharmacology, vol. 385, no. 1, pp. 197–207, 2008.

[4] L. Nelson and N. Tabet, ”Slowing the progression of Alzheimer’s disease: what works?,” Ageing Research Reviews, vol. 23, pp. 193–209, 2015.

[5] S. J. Shewale, R. M. Hubsinger, M. S. Allen, and R. C. Barber, ”The potential role of epigenetics in Alzheimer’s disease etiology,” Biological Systems: Open Access, vol. 2, no. 3, p. 114, 2013.

[6] S. S. M. Fernández and S. M. L. Ribeiro, ”Nutrition and Alzheimer disease,” Clinics in Geriatric Medicine, vol. 34, no. 4, pp. 677–697, 2018.

[7] D. Athanasopoulos, G. Karagiannis, and M. Tsolaki, ”Recent findings in Alzheimer disease and nutrition focusing on epigenetics,” Advances in Nutrition, vol. 7, no. 5, pp. 917–927, 2016.

[8] V. Nicolia, M. Lucarelli, and A. Fusco, ”Environment, epigenetics and neurodegeneration: focus on nutrition in Alzheimer’s disease,” Experimental Gerontology, vol. 68, pp. 8–12, 2015.

[9] D. R. Gustafson, M. Clare Morris, N. Scarmeas et al., “New perspectives on Alzheimer’s disease and nutrition,” Journal of Alzheimer’s Disease, vol. 46, no. 4, pp. 1111–1127, 2015.

[10] R. Shah, ”The role of nutrition and diet in Alzheimer disease: a systematic review,” Journal of the American Medical Directors Association, vol. 14, no. 6, pp. 398–402, 2013.

[11] C. Y. Santos, P. J. Snyder, W. C. Wu, M. Zhang, A. Echeverria, and J. Alber, ”Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular
risk: a review and synthesis,” *Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring*, vol. 7, pp. 69–87, 2017.

[12] A. D. Dangour, P. J. Whitehouse, K. Rafferty et al., “B-vitamins and fatty acids in the prevention and treatment of Alzheimer’s disease and dementia: a systematic review,” *Journal of Alzheimer’s Disease*, vol. 22, no. 1, pp. 205–224, 2010.

[13] M. W. Schelke, K. Hackett, J. L. Chen et al., “Nutritional interventions for Alzheimer’s prevention: a clinical precision medicine approach,” *Annals of the New York Academy of Sciences*, vol. 1367, no. 1, pp. 50–56, 2016.

[14] L. E. Middleton and K. Yaffe, “Promising strategies for the prevention of dementia,” *Archives of Neurology*, vol. 66, no. 10, pp. 1210–1215, 2009.

[15] M. O. W. Grimm, D. M. Michaelson, and T. Hartmann, “Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer’s disease: a rationale for multi-nutrient dementia prevention,” *Journal of Lipid Research*, vol. 58, no. 11, pp. 2083–2101, 2017.

[16] K. Fischer, D. Melo van Lent, S. Wolfsgruber et al., “Prospective associations between single foods, Alzheimer’s dementia and memory decline in the elderly,” *Nutrients*, vol. 10, no. 7, p. 852, 2018.

[17] S. K. Ravi, R. B. Narasingappa, and B. Vincent, “Neuro-nutrients as anti-Alzheimer’s disease agents: a critical review,” *Critical Reviews in Food Science and Nutrition*, vol. 30, pp. 1–20, 2018.

[18] O. van de Rest, A. A. M. Berendsen, A. Haveman-Nies, and L. C. P. G. M. de Groot, “Dietary patterns, cognitive decline, and dementia: a systematic review,” *Advances in Nutrition*, vol. 6, no. 2, pp. 154–168, 2015.

[19] A. Knight, J. Bryan, and K. Murphy, “Is the Mediterranean diet a feasible approach to preserving cognitive function and reducing risk of dementia for older adults in Western countries? New insights and future directions,” *Ageing Research Reviews*, vol. 25, pp. 85–101, 2016.

[20] V. Solfirizi, V. Frisardi, D. Seripa et al., “Mediterranean diet in predementia and dementia syndromes,” *Current Alzheimer Research*, vol. 8, no. 5, pp. 520–542, 2011.

[21] V. Solfirizi and F. Panza, “Mediterranean diet and cognitive decline. A lesson from the whole-diet approach: what challenges lie ahead?,” *Journal of Alzheimer’s Disease*, vol. 39, no. 2, pp. 283–286, 2014.

[22] N. Scarmeas, Y. Stern, R. Mayeux, and J. A. Luchsinger, “Mediterranean diet, Alzheimer disease, and vascular mediation,” *Archives of Neurology*, vol. 63, no. 12, pp. 1709–1717, 2006.

[23] S. Gardener, Y. Gu, S. R. Rainey-Smith et al., “Adherence to a Mediterranean diet and Alzheimer’s disease risk in an Australian population,” *Translational Psychiatry*, vol. 2, no. 10, article e164, 2012.

[24] A. Trichopoulou, T. Costacou, C. Bamia, and D. Trichopoulou, “Adherence to a Mediterranean diet and survival in a Greek population,” *New England Journal of Medicine*, vol. 348, no. 26, pp. 2599–2608, 2003.

[25] N. Scarmeas, Y. Stern, M. X. Tang, R. Mayeux, and J. A. Luchsinger, “Mediterranean diet and risk for Alzheimer’s disease,” *Annals of Neurology*, vol. 59, no. 6, pp. 912–921, 2006.

[26] N. Scarmeas, J. A. Luchsinger, N. Schupf et al., “Physical activity, diet, and risk of Alzheimer disease,” *JAMA*, vol. 302, no. 6, pp. 627–637, 2009.

[27] Y. Gu, J. A. Luchsinger, Y. Stern, and N. Scarmeas, “Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer’s disease,” *Journal of Alzheimer’s Disease*, vol. 22, no. 2, pp. 483–492, 2010.

[28] M. C. Morris, C. C. Tangney, Y. Wang et al., “MIND diet slows cognitive decline with aging.” *Alzheimer’s & Dementia*, vol. 11, no. 9, pp. 1015–1022, 2015.

[29] N. Scarmeas, Y. Stern, R. Mayeux, J. J. Manly, N. Schupf, and J. A. Luchsinger, “Mediterranean diet and mild cognitive impairment,” *Archives of Neurology*, vol. 66, no. 2, pp. 216–225, 2009.

[30] N. Scarmeas, J. A. Luchsinger, R. Mayeux, and Y. Stern, “Mediterranean diet and Alzheimer disease mortality,” *Neurology*, vol. 69, no. 11, pp. 1084–1093, 2007.

[31] C. A. Anastasiou, M. Yannakoulia, M. H. Kosmidis et al., “Mediterranean diet and cognitive health: initial results from the Hellenic Longitudinal Investigation of Ageing and Diet,” *PloS One*, vol. 12, no. 8, article e0182048, 2017.

[32] D. B. Panagiotakos, C. Pitsavos, F. Arvaniti, and C. Stefanadis, “Adherence to the Mediterranean food pattern predicts the prevalence of hypertension, hypercholesterolemia, diabetes and obesity, among healthy adults; the accuracy of the MedDietScore,” *Preventive Medicine*, vol. 44, no. 4, pp. 335–340, 2007.

[33] C. Féart, C. Samieri, V. Rondeau et al., “Adherence to a Mediterranean diet, cognitive decline, and risk of dementia,” *JAMA*, vol. 302, no. 6, pp. 638–648, 2009.

[34] R. O. Roberts, Y. E. Geda, J. R. Cerrhan et al., “Vegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairment,” *Dementia and Geriatric Cognitive Disorders*, vol. 29, no. 5, pp. 413–423, 2010.

[35] E. Olsson, B. Karlström, L. Kiland, L. Byberg, T. Cederholm, and P. Sjögren, “Dietary patterns and cognitive dysfunction in a 12-year follow-up study of 70 year old men,” *Journal of Alzheimer’s Disease*, vol. 43, no. 1, pp. 109–119, 2015.

[36] T. Psaltopoulou, T. N. Sergentanis, D. B. Panagiotakos, I. N. Sergentanis, R. Kosti, and N. Scarmeas, "Mediterranean diet, stroke, cognitive impairment, and depression: a meta-analysis," *Annals of Neurology*, vol. 74, no. 4, pp. 580–591, 2013.

[37] F. Soli, R. Abbate, G. F. Gensini, and A. Casini, “Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis,” *The American Journal of Clinical Nutrition*, vol. 92, no. 5, pp. 1189–1196, 2010.

[38] B. Singh, A. K. Parsaik, M. M. Mielke et al., “Association of Mediterranean diet with mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis,” *Journal of Alzheimer’s Disease*, vol. 39, no. 2, pp. 271–282, 2014.

[39] S. D. Petersson and E. Philippou, "Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence," *Advances in Nutrition*, vol. 7, no. 5, pp. 889–904, 2016.

[40] Y. S. Aridi, J. L. Walker, and O. R. L. Wright, "The association between the Mediterranean dietary pattern and cognitive health: a systematic review," *Nutrients*, vol. 9, no. 7, p. 674, 2017.

[41] M. Yusufov, L. L. Weyandt, and I. Piryatinskaya, "Alzheimer’s disease and diet: a systematic review," *International Journal of Neuroscience*, vol. 127, no. 2, pp. 161–175, 2017.
preserved brain structural connectivity in older subjects,

American Journal of Clinical Nutrition
vol. 48, no. 12, pp. 1443–1456, 2013.

Mediterranean diet and age-related cognitive decline: a randomized clinical trial, JAMA Internal Medicine, vol. 175, no. 7, pp. 1094–1103, 2015.

A. M. Luciano, J. Ros, J. Salas-Salvadó et al., “Primary prevention of cardiovascular disease with a Mediterranean diet,” New England Journal of Medicine, vol. 368, no. 14, pp. 1279–1290, 2013.

E. H. Martínez-Lapiscina, P. Clavero, E. Toledo et al., “Mediterranean diet improves cognition: the PREMID-NAVARRA randomised trial,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 84, no. 12, pp. 1318–1325, 2013.

C. Valls-Pedret, A. Sala-Vila, M. Serra-Mir et al., “Mediterranean diet and brain structure in a multiethnic elderly cohort,” Neurology, vol. 85, no. 20, pp. 1744–1751, 2015.

F. M. Sacks, L. P. Svetkey, W. M. Vollmer et al., “Effects of the Dietary Approaches to Stop Hypertension diet, cognitive function, and cognitive decline in American older women, The American Journal of Clinical Nutrition, vol. 18, no. 5, pp. 427–432, 2017.

R. Estruch, M. Á. Martínez-González, D. Corella et al., “Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial,” Annals of Internal Medicine, vol. 145, no. 1, pp. 1–11, 2006.

C. Chrysostohou, D. B. Panagiotakos, C. Pittavos, U. N. Das, and C. Stefanadis, “Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: the Attica study,” Journal of the American College of Cardiology, vol. 44, no. 1, pp. 152–158, 2004.

R. Casas, E. Sacanella, M. Urpi-Sardà et al., “The effects of the Mediterranean diet on biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for cardiovascular disease. A randomized trial,” PLoS One, vol. 9, no. 6, article e100084, 2014.

D. C. Matthews, M. Davies, J. Murray et al., “Physical activity, Mediterranean diet and biomarkers-assessed risk of Alzheimer’s: a multi-modality brain imaging study,” Advances in Molecular Imaging, vol. 4, no. 4, pp. 43–57, 2014.

M. Vassilaki, J. A. Aakre, J. A. Syrjanen et al., “Mediterranean diet, its components, and amyloid imaging biomarkers,” Journal of Alzheimer’s Disease, vol. 64, no. 1, pp. 281–290, 2018.

S. R. Rainey-Smith, Y. Gu, S. L. Gardener et al., “Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: data from the Australian imaging, biomarkers and lifestyle study of ageing,” Translational Psychiatry, vol. 8, no. 1, p. 238, 2018.

S. C. Staubo, J. A. Aakre, P. Venmuri et al., “Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness,” Alzheimers & Dementia, vol. 13, no. 2, pp. 168–177, 2017.

L. Mosconi, J. Murray, W. H. Tsui et al., “Mediterranean diet and magnetic resonance imaging-assessed brain atrophy in cognitively normal individuals at risk for Alzheimer’s disease,” The Journal of Prevention of Alzheimer’s Disease, vol. 1, no. 1, pp. 23–32, 2014.

A. J. Karstens, L. Tussing-Humphreys, L. Zhan et al., “Associations of the Mediterranean diet with cognitive and neuroimaging phenotypes of dementia in healthy older adults,” The American Journal of Clinical Nutrition, vol. 109, no. 2, pp. 361–368, 2019.

M. Luciano, J. Corley, S. R. Cox et al., “Mediterranean-type diet and brain structural change from 73 to 76 years in a Scottish cohort,” Neurology, vol. 88, no. 5, pp. 449–455, 2017.

F. N. Jacka, N. Cherbuin, K. J. Anstey, P. Sachdev, and P. Butterworth, “Western diet is associated with a smaller hippocampus: a longitudinal investigation,” BMC Medicine, vol. 13, no. 1, p. 215, 2015.

B. Haring, C. Wu, L. H. Coker et al., “Hypertension, dietary sodium, and cognitive decline: results from the Women’s Health Initiative Memory Study,” American Journal of Hypertension, vol. 29, no. 2, pp. 202–216, 2016.
[71] P. J. Smith, J. A. Blumenthal, M. A. Babyak et al., "Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure," *Hypertension*, vol. 55, no. 6, pp. 1331–1338, 2010.

[72] N. Di Fiore, "Diet may help prevent Alzheimer's: MIND diet rich in vegetables, berries, whole grains, nuts" Rush University Medical Center website [https://www.rush.edu/new/diet-may-hel-prevent-alzheimers](https://www.rush.edu/new/diet-may-hel-prevent-alzheimers).

[73] M. Koch and M. K. Jensen, "Association of the MIND diet with cognition and risk of Alzheimer’s disease," *Current Opinion in Lipidology*, vol. 27, no. 3, pp. 303–304, 2016.

[74] J. Kang, A. Ascherio, and F. Grodstein, "Modulation of Nrf2 by olive oil and wine polyphenols and polyunsaturated fatty acids, improves mouse cognitive decline associated with aging and Alzheimer’s disease," *Behavioural Brain Research*, vol. 228, no. 2, pp. 261–271, 2012.

[75] L. Fernández-Fernández, G. Comes, I. Bolea et al., "LMN diet, rich in polyphenols and polysaturated fatty acids, improves mouse cognitive decline associated with aging and Alzheimer’s disease," *Behavioural Brain Research*, vol. 228, no. 2, pp. 261–271, 2012.

[76] C. Grossi, S. Rigacci, S. Ambrosini et al., "The polyphenol oleuropein aglycone protects TgCRND8 mice against Aβ plaque pathology," *PLoS One*, vol. 8, no. 8, article e71702, 2013.

[77] M. C. Morris, D. A. Evans, C. C. Tangney, J. L. Bienias, and B. Shukitt-Hale, V. Cheng, and J. A. Joseph, "Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats," *Nutritional Neuroscience*, vol. 75, no. 6, pp. 442–451, 2010.

[78] D. H. Malin, D. R. Lee, P. Goyarzu et al., "Bioavailability of dietary polyphenols: factors contributing to their clinical application in CNS diseases," *Neurochemistry International*, vol. 89, pp. 198–208, 2015.

[79] E. Kelly, P. Vyas, and J. Weber, "Biochemical properties and neuroprotective effects of compounds in various species of berries," *Molecules*, vol. 23, no. 1, p. 26, 2018.

[80] E. E. Devore, J. H. Kang, M. M. B. Breteler, and F. Grodstein, "Dietary intakes of berries and flavonoids in relation to cognitive decline," *Annals of Neurology*, vol. 72, no. 1, pp. 135–143, 2012.
[102] H. Zrelli, M. Matsuoka, S. Kitazaki et al., “Hydroxytyrosol induces proliferation and cytoprotection against oxidative injury in vascular endothelial cells: role of Nrf2 activation and HO-1 induction,” Journal of Agricultural and Food Chemistry, vol. 59, no. 9, pp. 4473–4482, 2011.

[103] M. H. Ahmad, M. Fatima, and A. C. Mondal, “Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimer’s disease: rational insights for the therapeutic approaches,” Journal of Clinical Neuroscience, vol. 59, pp. 6–11, 2019.

[104] R. Takamura, N. Watamura, M. Nikkuni, and T. Ohshima, “All-trans retinoic acid improved impaired proliferation of neural stem cells and suppressed microglial activation in the hippocampus in an Alzheimer’s mouse model,” Journal of Neuroscience Research, vol. 95, no. 3, pp. 897–906, 2017.

[105] S. Mishra, K. K. Kelly, N. L. Rumian, and J. A. Siegenthaler, “Retinoic acid is required for neural stem and progenitor cell proliferation in the adult hippocampus,” Stem Cell Reports, vol. 10, no. 6, pp. 1705–1720, 2018.

[106] F. Regen, J. Hellmann-Regen, E. Costantini, and M. Reale, “Neuroinflammation and Alzheimer’s disease: implications for microglial activation,” Current Alzheimer Research, vol. 14, no. 11, pp. 1140–1148, 2017.

[107] M. T. Heneka, M. J. Carson, J. E. Khoury et al., “F. Regen, J. Hellmann-Regen, E. Costantini, and M. Reale, “Neuroinflammation and Alzheimer’s disease: implications for microglial activation,” Current Alzheimer Research, vol. 14, no. 11, pp. 1140–1148, 2017.

[108] A. A. Raha, J. W. Henderson, S. R. Stott et al., “Neuroprotective effect of TREM-2 in aging and Alzheimer’s disease model,” Journal of Alzheimer’s Disease, vol. 55, no. 1, pp. 199–217, 2017.

[109] S. Krassmann, C. Madore, R. Cialic et al., “The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases,” Immunity, vol. 47, no. 3, pp. 566–581.e9, 2017.

[110] F. G. De Felice and S. T. Ferreira, “Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease,” Diabetes, vol. 63, no. 7, pp. 2262–2272, 2014.

[111] J. P. Bastard, M. Maachi, C. Lagathu et al., “Recent advances in the relationship between obesity, inflammation, and insulin resistance,” European Cytokine Network, vol. 17, no. 1, pp. 4–12, 2006.

[112] K. Ono, M. Hirohata, and M. Yamada, “Ferulic acid destabilizes preformed β-amyloid fibrils in vitro,” Biochemical and Biophysical Research Communications, vol. 336, no. 2, pp. 444–449, 2005.

[113] T. Hamaguchi, K. Ono, A. Murase, and M. Yamada, “Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid-β aggregation pathway,” The American Journal of Pathology, vol. 175, no. 6, pp. 2557–2565, 2009.

[114] J. J. Yan, J. Y. Cho, H. S. Kim et al., “Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid,” British Journal of Pharmacology, vol. 133, no. 1, pp. 89–96, 2001.

[115] R. Sultana, A. Ravagna, H. Mohmmad-Abdul, V. Calabrese, and D. A. Butterfield, “Ferulic acid ethyl ester protects neurons against amyloid β-peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity,” Journal of Neurochemistry, vol. 92, no. 4, pp. 749–758, 2005.

[116] T. Shen, X. N. Wang, and H. X. Lou, “Natural stilbenes: an overview,” Natural Product Reports, vol. 26, no. 7, pp. 916–935, 2009.

[117] S. P. Patil, N. Tran, H. Geekiyanage, L. Liu, and C. Chan, “Curcumin-induced upregulation of the anti-tau cochaperone BAG2 in primary rat cortical neurons,” Neuroscience Letters, vol. 554, pp. 121–125, 2013.

[118] C. A. Ribeiro, M. J. Saravia, and I. Cardoso, “Stability of the transthyretin molecule as a key factor in the interaction with α-peptide - relevance in Alzheimer’s disease,” PLoS One, vol. 7, no. 9, article e45368, 2012.

[119] K. J. Kwon, H. J. Kim, C. Y. Shin, and S. H. Han, “Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating amp-activated protein kinase pathways,” Journal of Clinical Neurology, vol. 6, no. 3, pp. 127–137, 2010.

[120] K. J. Kwon, J. N. Kim, M. K. Kim et al., “Melatonin synergistically increases resveratrol induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: a possible role in neuroprotection,” Journal of Pineal Research, vol. 50, no. 2, pp. 110–123, 2011.

[121] X. Cheng, Q. Wang, N. Li, and H. Zhao, “Effects of resveratrol on hippocampal astrocytes and expression of TNF-α in Alzheimer’s disease model rate,” Wei Sheng Yan Jiu, vol. 44, no. 4, pp. 610–614, 2015.

[122] Y. Kim, S. Y. Lim, S. H. Rhee et al., “Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells,” International Journal of Molecular Medicine, vol. 17, no. 6, pp. 1069–1075, 2006.

[123] S. Laye, A. Nadjar, C. Joffre, and R. P. Bazinet, “Anti-inflammatory effects of omega-3 fatty acids in the brain: physiological mechanisms and relevance to pharmacology,” Pharmacological Reviews, vol. 70, no. 1, pp. 12–38, 2018.

[124] T. Kavanagh, P. E. Lonergan, and M. A. Lynch, “Eicosapentaenoic acid and gamma-linolenic acid increase hippocampal concentrations of IL-4 and IL-10 and abrogate lipopolysaccharide-induced inhibition of long-term potentiation,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 70, no. 4, pp. 391–397, 2004.

[125] E. Teng, K. Taylor, T. Biloosova et al., “Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and fibril pathology and modulates Aβ oligomerization,” Neurobiology of Disease, vol. 82, pp. 552–560, 2015.

[126] A. B. Segarra, J. I. Ruiz-Sanz, M. B. Ruiz-Larrea et al., “The profile of fatty acids in frontal cortex of rats depends on the type of fat used in the diet and correlates with neuropeptidase activities,” Hormone and Metabolic Research, vol. 43, no. 2, pp. 86–91, 2011.

[127] The Human Microbiome Project Consortium, “Structure, function and diversity of the healthy human microbiome,” Nature, vol. 486, no. 7402, pp. 207–214, 2012.

[128] P. B. Eckburg, E. M. Bik, C. N. Bernstein et al., “Diversity of the human intestinal microbial flora,” Science, vol. 308, no. 5728, pp. 1635–1638, 2005.

[129] L. Szablewski, “Human gut microbiota in health and Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 62, no. 2, pp. 549–560, 2018.
L. Shen and H. F. Ji, “Bidirectional interactions between dietary curcumin and gut microbiota,” Critical Reviews in Food Science and Nutrition, vol. 21, pp. 1–7, 2018.

J. S. Rane, P. Bhaumik, and D. Panda, “Curcumin inhibits tau aggregation and disintegrates preformed tau filaments in vitro,” Journal of Alzheimer’s Disease, vol. 60, no. 3, pp. 999–1014, 2017.

C. S. Oriach, R. C. Robertson, C. Stanton, J. F. Cryan, and T. G. Dinan, “Food for thought: the role of nutrition in the microbiota-gut-brain axis,” Clinical Nutrition Experimental, vol. 6, pp. 25–38, 2016.

M. K. Zinöcker and I. A. Lindseth, “The Western diet-microbiome-host interaction and its role in metabolic disease,” Nutrients, vol. 10, no. 3, p. 365, 2018.

T. W. Buford, “(Dis)trust your gut: the gut microbiome in age-related inflammation, health, and disease,” Microbiome, vol. 5, no. 1, p. 80, 2017.

A. M. Vaiserman, A. K. Koliada, and F. Marotta, “Gut microbiota: a player in aging and a target for anti-aging intervention,” Ageing Research Reviews, vol. 35, pp. 36–45, 2017.

S. C. Bischoff, “Microbiota and aging,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 19, no. 1, pp. 26–30, 2016.

P. C. Konturek, D. Haziri, T. Brzozowski et al., E. Biagi, L. Nylund, M. Candela et al., “A. Santoro, R. Ostan, M. Candela et al., “Microbiota and aging,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 19, no. 1, pp. 26–30, 2016.

P. C. Konturek, D. Haziri, T. Brzozowski et al., “Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases,” Journal of Physiology and Pharmacology, vol. 66, no. 4, pp. 483–491, 2015.

E. Biagi, L. Nylund, M. Candela et al., “Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians,” PLoS One, vol. 5, no. 5, article e10667, 2010.

M. J. Claesson, I. B. Jefferies, S. Conde et al., “Gut microbiota composition correlates with diet and health in the elderly,” Nature, vol. 488, no. 7410, pp. 178–184, 2012.

S. Mueller, K. Saunier, C. Hanisch et al., “Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study,” Applied and Environmental Microbiology, vol. 72, no. 2, pp. 1027–1033, 2006.

A. Santoro, R. Ostan, M. Candela et al., “Gut microbiota changes in the extreme decades of human life: a focus on centenarians,” Cellular and Molecular Life Sciences, vol. 75, no. 1, pp. 129–148, 2018.

K. A. Scott, M. Ida, V. L. Peterson et al., “Revisiting Metchnikoff: age-related alterations in microbiota-gut-brain axis in the mouse,” Brain, Behavior, and Immunity, vol. 65, pp. 20–32, 2017.

C. Bäuerl, M. C. Collado, A. Diaz-Cuevas, J. Viña, and G. Pérez Martinez, “Shifts in gut microbiota composition in an APP/PS1 transgenic mouse model of Alzheimer’s disease during lifespan,” Letters in Applied Microbiology, vol. 66, no. 6, pp. 464–471, 2018.

L. Zhang, Y. Wang, X. Xiayu et al., “Altered gut microbiota in a mouse model of Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 60, no. 4, pp. 1241–1257, 2017.

E. Sanguinetti, M. C. Collado, V. G. Marrachelli et al., “Microbiome-metabolome signatures in mice genetically prone to develop dementia, fed a normal or fatty diet,” Scientific Reports, vol. 8, no. 1, p. 4907, 2018.

T. Harach, N. Marungruang, N. Duthilleul et al., “Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota,” Scientific Reports, vol. 7, no. 1, article 41802, 2017.

M. R. Minter, C. Zhang, V. Leone et al., “Antibiotic-induced perturbations in gut microbial diversity influences neuroinflammation and amyloidosis in a murine model of Alzheimer’s disease,” Scientific Reports, vol. 6, no. 1, article 30028, 2016.

E. E. Fröhlich, A. Farzi, R. Mayerhofer et al., “Cognitive impairment by antibiotic-induced gut dysbiosis: analysis of gut microbiota-brain communication,” Brain, Behavior, and Immunity, vol. 56, pp. 140–155, 2016.

L. Boffili, V. Cecarini, S. Berardi et al., “Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels,” Scientific Reports, vol. 7, no. 1, article 2426, 2017.

N. Nimgampalle and Y. Kuna, “Anti-Alzheimer properties of probiotic, Lactobacillus plantarum MTCC 1325 in Alzheimer’s disease induced albino rats,” Journal of Clinical and Diagnostic Research, vol. 11, no. 8, pp. KCO1–KCO5, 2017.

Y. Kobayashi, H. Sugahara, K. Shimada et al., “Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease,” Scientific Reports, vol. 7, no. 1, p. 13510, 2017.

T. Chunchai, W. Thunapong, S. Yasm et al., “Decreased microglial activation through gut-brain axis by prebiotics, probiotics, or synbiotics effectively restored cognitive function in obese-insulin resistant rats,” Journal of Neuroinflammation, vol. 15, no. 1, p. 11, 2018.

C. Q. Li, Q. Zheng, Q. Wang, and Q. P. Zeng, “Bioci/adibiotic stress-driven Alzheimer’s disease,” Frontiers in Cellular Neuroscience, vol. 10, p. 269, 2016.

C. Hollands, N. Bartolotti, and O. Lazarov, “Alzheimer’s disease and hippocampal adult neurogenesis; exploring shared mechanisms,” Frontiers in Neuroscience, vol. 10, p. 178, 2016.

O. Lazarov and R. A. Marr, “Neurogenesis and Alzheimer’s disease: at the crossroads,” Experimental Neurology, vol. 223, no. 2, pp. 267–281, 2010.

S. Das and A. Basu, “Inflammation: a new candidate in modulating adult neurogenesis,” Journal of Neuroscience Research, vol. 86, no. 6, pp. 1199–1208, 2008.

R. Molteni, R. J. Barnard, Z. Ying, C. K. Roberts, and F. Gomez-Pinilla, “A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning,” Neuroscience, vol. 112, no. 4, pp. 803–814, 2002.

M. Futshi, P. Mohassel, and K. Yaffe, “Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association,” Nature Clinical Practice Neurology, vol. 5, no. 3, pp. 140–152, 2009.

A. Granzotto and P. Zatta, “Resveratrol and Alzheimer’s disease: message in a bottle on red wine and cognition,” Frontiers in Aging Neuroscience, vol. 6, p. 95, 2014.

P. Scheltens, K. Blennow, M. M. B. Breteler et al., “Alzheimer’s disease,” The Lancet, vol. 388, no. 10043, pp. 505–517, 2016.

M. P. Mattson and T. V. Arumugam, “Hallmarks of brain aging: adaptive and pathological modification by metabolic states,” Cell Metabolism, vol. 27, no. 6, pp. 1176–1199, 2018.

D. Wahl, V. C. Cogger, S. M. Solon-Biet et al., “Nutritional strategies to optimise cognitive function in the aging brain,” Ageing Research Reviews, vol. 31, pp. 80–92, 2016.
[163] S. Camandola and M. P. Mattson, “Brain metabolism in health, aging and neurodegeneration,” *The EMBO Journal*, vol. 36, no. 11, pp. 1474–1492, 2017.

[164] V. D. Longo and M. P. Mattson, “Fasting: molecular mechanisms and clinical applications,” *Cell Metabolism*, vol. 19, no. 2, pp. 181–192, 2014.

[165] L. Fontana, L. Partridge, and V. D. Longo, “Extending healthy life span—from yeast to humans,” *Science*, vol. 328, no. 5976, pp. 321–326, 2010.

[166] S. Golbidi, A. Daiber, B. Korac, H. Li, M. F. Essop, and I. Laher, “Health benefits of fasting and caloric restriction,” *Current Diabetes Reports*, vol. 17, no. 12, p. 123, 2017.

[167] A. J. Bruce-Keller, G. Umberger, R. McFall, and M. P. Mattson, “Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults,” *Annals of Neurology*, vol. 45, no. 1, pp. 8–15, 1999.

[168] R. M. Anson, Z. Guo, R. de Cabo et al., “Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake,” *Proceedings of the National Academy of Sciences of the United States America*, vol. 100, no. 10, pp. 6216–6220, 2003.

[169] J. B. Johnson, W. Summer, R. G. Cutler et al., “Alternate day caloric restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma,” *Free Radical Biology & Medicine*, vol. 42, no. 5, pp. 665–674, 2007.

[170] K. A. Varady, V. T. Dam, M. C. Klempp et al., “Effects of weight loss via high fat vs. low fat alternate day fasting diets on free fatty acid profiles,” *Scientific Reports*, vol. 5, no. 1, article 7561, 2015.

[171] M. N. Harvie, M. Peginton, M. P. Mattson et al., “The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women,” *International Journal of Obesity*, vol. 35, no. 5, pp. 714–727, 2011.

[172] S. Brandhorst, I. Y. Choi, M. Wei et al., “A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance and healthspan,” *Cell Metabolism*, vol. 22, no. 1, pp. 86–99, 2015.

[173] I. Y. Choi, L. Piccio, P. Childress et al., “A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms,” *Cell Reports*, vol. 15, no. 10, pp. 2136–2146, 2016.

[174] M. P. Mattson, K. Moehl, N. Ghena, M. Schmaedick, and A. Cheng, “Intermittent metabolic switching, neuroplasticity and brain health,” *Nature Reviews Neuroscience*, vol. 19, no. 2, pp. 80–80, 2018.

[175] K. Marosi and M. P. Mattson, “BDNF mediates adaptive brain and body responses to energetic challenges,” *Trends in Endocrinology & Metabolism*, vol. 25, no. 2, pp. 89–98, 2014.

[176] R. A. H. van de Ven, D. Santos, and M. C. Haigis, “Mitochondrial sirtuins and molecular mechanisms of aging,” *Trends in Molecular Medicine*, vol. 23, no. 4, pp. 320–331, 2017.

[177] A. Cheng, R. Wan, J. L. Yang et al., “Involvement of PGC-1α in the formation and maintenance of neuronal dendritic spines,” *Nature Communications*, vol. 3, no. 1, article 1250, 2012.

[178] T. V. Arumugam, T. M. Phillips, A. Cheng, C. H. Morrell, M. P. Mattson, and R. Wan, “Age and energy intake interact to modify cell stress pathways and stroke outcome,” *Annals of Neurology*, vol. 67, no. 1, pp. 41–52, 2010.

[179] S. C. Johnson, P. S. Rabinovitch, and M. Kaeberlein, “mTOR is a key modulator of ageing and age-related disease,” *Nature*, vol. 493, no. 7432, pp. 338–345, 2013.

[180] M. Laplante and D. M. Sabatini, “mTOR signaling in growth control and disease,” *Cell*, vol. 149, no. 2, pp. 274–292, 2012.

[181] R. Singh, D. Lakanpal, S. Kumar et al., “Late-onset intermittent fasting dietary restriction as a potential intervention to retard age-associated brain function impairments in male rats,” *Age*, vol. 34, no. 4, pp. 917–933, 2012.

[182] R. Singh, S. Manchanda, T. Kaur et al., “Middle age onset short-term intermittent fasting dietary restriction prevents brain function impairments in male Wistar rats,” *Biogerontology*, vol. 16, no. 6, pp. 775–788, 2015.

[183] Á. Fontán-Lozano, J. L. Saez-Casanelli, M. C. Inda et al., “Caloric restriction increases learning consolidation and facilitates synaptic plasticity through mechanisms dependent on NR2B subunits of the NMDA receptor,” *The Journal of Neuroscience*, vol. 27, no. 38, pp. 10185–10195, 2007.

[184] L. Li, Z. Wang, and Z. Zuo, “Chronic intermittent fasting improves cognitive functions and brain structures in mice,” *PloS One*, vol. 8, no. 6, article e66069, 2013.

[185] W. Duan, Z. H. Guo, and M. P. Mattson, “Brain-derived neurotrophic factor mediates an excitoprotective effect of dietary restriction in mice,” *Journal of Neurochemistry*, vol. 76, no. 2, pp. 619–626, 2001.

[186] H. van Praag, B. R. Christie, T. J. Sejnowski, and F. H. Gage, “Running enhances neurogenesis, learning, and long-term potentiation in mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 23, pp. 13427–13431, 1999.

[187] R. M. O’Callaghan, R. Ohle, and Á. M. Kelly, “The effects of forced exercise on hippocampal plasticity in the rat: a comparison of LTP, spatial- and non-spatial learning,” *Behavioural Brain Research*, vol. 176, no. 2, pp. 362–366, 2007.

[188] K. Eckles-Smith, D. Clayton, P. Bickford, and M. D. Browning, “Caloric restriction prevents age-related deficits in LTP and in NMDA receptor expression,” *Molecular Brain Research*, vol. 78, no. 1–2, pp. 154–162, 2000.

[189] N. Hori, I. Hirotsu, P. J. Davis, and D. O. Carpenter, “Long-term potentiation is lost in aged rats but preserved by calorie restriction,” *Neuroreport*, vol. 3, no. 12, pp. 1085–1088, 1992.

[190] V. K. M. Halagappa, Z. Guo, M. Pearson et al., “Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer’s disease,” *Neurobiology of Disease*, vol. 26, no. 1, pp. 212–220, 2007.

[191] N. V. Patel, M. N. Gordon, K. E. Connor et al., “Caloric restriction attenuates βF-deposition in Alzheimer transgenic models,” *Neurobiology of Aging*, vol. 26, no. 7, pp. 995–1000, 2005.

[192] J. Wang, L. Ho, W. Qin et al., “Caloric restriction attenuates β-amyloid neuropathology in a mouse model of Alzheimer’s disease,” *The FASEB Journal*, vol. 19, no. 6, pp. 659–661, 2005.

[193] P. R. Mouton, M. E. Chachich, C. Quigley, E. Spangler, and D. K. Ingram, “Caloric restriction attenuates amyloid deposition in middle-aged dtg APP/PS1 mice,” *Neuroscience Letters*, vol. 464, no. 3, pp. 184–187, 2009.
[194] E. Parrella, T. Maxim, F. Maialetti et al., “Protein restriction cycles reduce IGF-1 and phosphorylated tau and improve behavioral performance in an Alzheimer’s disease mouse model,” Aging Cell, vol. 12, no. 2, pp. 257–268, 2013.

[195] J. Zhang, Z. Zhan, X. Li et al., “Intermittent fasting protects against Alzheimer’s disease possible through restoring aquaporin-4 polarity,” Frontiers in Molecular Neuroscience, vol. 10, p. 395, 2017.

[196] J. Lee, K. B. Seroogy, and M. P. Mattson, “Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice,” Journal of Neurochemistry, vol. 80, no. 3, pp. 539–547, 2002.

[197] C. Vivar, M. C. Potter, J. Choi et al., “Monosynaptic inputs to new neurons in the dentate gyrus,” Nature Communications, vol. 3, no. 1, article 1107, 2012.

[198] J. F. Trepanowski, C. M. Kroeger, A. Barnosky et al., “Effect of alternate-day fasting on weight loss, weight maintenance, and cardioprotection among metabolically healthy obese adults,” JAMA Internal Medicine, vol. 177, no. 7, pp. 930–938, 2017.

[199] M. Wei, S. Brandhorst, M. Shelehchi et al., “Fasting-mimicking diet and markers/risk factors for aging, diabetes cancer and cardiovascular disease,” Science Translational Medicine, vol. 9, no. 377, article eeai8700, 2017.

[200] H. Mirzaei, J. A. Suarez, and V. D. Longo, “Protein and amino acid restriction, aging and disease: from yeast to humans,” Trends in Endocrinology & Metabolism, vol. 25, no. 11, pp. 558–566, 2014.

[201] M. E. Levine, J. A. Suarez, S. Brandhorst et al., “Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population,” Cell Metabolism, vol. 19, no. 3, pp. 407–417, 2014.

[202] A. V. Witte, M. Fobker, R. Gellner, S. Knecht, and A. Floel, “Caloric restriction improves memory in elderly humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 4, pp. 1255–1260, 2009.

[203] J. L. Bayer-Carter, P. S. Green, T. J. Montine et al., “Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment,” Archives of Neurology, vol. 68, no. 6, pp. 743–752, 2011.

[204] C. W. Cheng, V. Villani, R. Buono et al., “Fasting-mimicking diet promotes Ngn3-driven β-cell regeneration to reverse diabetes,” Cell, vol. 168, no. 5, pp. 775–788.e12, 2017.